Home

Henrik Enghusen Poulsen

MD, DMSci, Professor

WELCOME

TO THE WEBSITE OF

HENRIK ENGHUSEN POULSEN

INTRODUCTION

ABOUT HENRIK



Henrik Enghusen Poulsen took his medical diploma in 1976, and 10 years later he became dr. med. at the University of Copenhagen. From 1996 he has been professor of the Laboratory of Clinical Pharmacology  in Copenhagen. He regularly presents at national and international meetings, and has conducted numerous research studies.

LABORATORY OF CLINICAL PHARMACOLOGY COPENHAGEN

 

Clinical pharmacology is the science of therapeutics. The full potential of clinical pharmacology will be achieved only by research.

 

Advances made over the past decade, a description of diseases in molecular terms, improves the ways in which human diseases are detected, classified, monitored, and treated. Diseases such as heart disease, diabetes, and cancer.

In the laboratory we study biomarkers, pharmacokinetics, drug metabolism and genetics. 


RECENT WORK



We investigate if a marker in the urine can indicate mortality in type 2 diabetes


The overall aim of my study is to identify an intervention that reduces oxidative stress measured by 8-oxoGuo in patients with for instance type 2 diabetes.

The past decade has provided exciting insights into the role of oxidative stress in the development of for all degenerative deseases.

CONTACT DETAILS

Laboratory of Clinical Pharmacology Q, Rigshospitalet, Ole Maal√łes Vej 26,  section Q7642, DK-2200 Copenhagen, Denmark

(45)  3545 7642

LATEST NEWS


June 2017

Oxidative nucleic acid modifications in patients with type 2 diabetes.


June 2016

Increased DNA and RNA damage by oxidation in patients with bipolar I disorder.

BIOMARKER IN DIABETES


Evidence suggests that oxidative stress has an important role in the pathogenesis of diabetes complications


Urinary excretion of the RNA oxidation marker 8-oxoGuo measured shortly after diagnosis of type 2 diabetes predicts long-term mortality independently of conventional risk factors. This finding suggests that 8-oxoGuo could serve as a new clinical biomarker in diabetes.

Copyright @ All Rights Reserved